摘要
目的:评估自体CIK细胞治疗对改善化疗后晚期乳腺癌患者机体免疫力及生活质量的疗效及安全性。方法:通过开放的、非随机同期对照研究,比较自体CIK细胞治疗与一般对症治疗对化疗后晚期乳腺癌患者外周血T淋巴细胞亚群的影响,运用E-ORTC QLQ-C30生活质量测评量表分析CIK治疗前后患者生活质量改变,观察不良反应。结果:CIK治疗对化疗后晚期乳腺癌患者外周血CD3+、CD3+CD4+、CD3+CD56+T细胞亚群的升高作用优于一般对症治疗,自体CIK细胞治疗后患者临床症状、躯体功能及总健康状况较治疗前有明显改善,无严重不良反应。结论:自体CIK细胞对改善化疗后晚期乳腺癌患者机体免疫力及生活质量有较好疗效及安全性。
Objective： To assess the efficacy and toxicity of autologous CIK cells for improving immunity and quality of live in post-chemotherapy patients of advanced breast cancer. Methods： Compare the efficacy on T lymphocytes in peripheral blood of post-chemotherapy patients of advanced breast cancer from autologous CIK cells treatment to normal treatment by an open-label non-ran-domized concurrent controlled study. The quality of life in pre-treatment and post-treatment patients was measured by EORTC QLQ-C30, and the toxicity was monitored. Results： CD3^＋, CD3^＋CD4^＋, CD3^＋CD56^＋ T lymphocytes could be improved by autologous CIK cells treatment better than normal treatment. The quality of life was improved by autologous CIK cells treatment with no serious toxicity. Conclusion： The autologous CIK cells treatment was effective and safe for post-chemotherapy patients of advanced breast cancer.
出处
《现代生物医学进展》
CAS
2012年第32期6316-6320,共5页
Progress in Modern Biomedicine
基金
辽宁省自然科学基金资助项目(20082070)
